Cargando…

Schlafen family member 11 indicates favorable prognosis of patients with head and neck cancer following platinum-based chemoradiotherapy

Recently, Schlafen family member 11 (SLFN11) has been reported to increase the sensitivity of cancer cells to DNA-damaging agents, including platinum derivatives; thus, SLFN11 may be a predictive biomarker for platinum-based chemoradiotherapy (CRT). In this study, we examined whether SLFN11 expressi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamada, Seijiro, Kano, Satoshi, Murai, Junko, Suzuki, Takayoshi, Tsushima, Nayuta, Mizumachi, Takatsugu, Suzuki, Masanobu, Takashima, Tsuyoshi, Taniyama, Daiki, Sakamoto, Naoya, Fujioka, Yoichiro, Ohba, Yusuke, Homma, Akihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892834/
https://www.ncbi.nlm.nih.gov/pubmed/36741698
http://dx.doi.org/10.3389/fonc.2022.978875
_version_ 1784881395521290240
author Hamada, Seijiro
Kano, Satoshi
Murai, Junko
Suzuki, Takayoshi
Tsushima, Nayuta
Mizumachi, Takatsugu
Suzuki, Masanobu
Takashima, Tsuyoshi
Taniyama, Daiki
Sakamoto, Naoya
Fujioka, Yoichiro
Ohba, Yusuke
Homma, Akihiro
author_facet Hamada, Seijiro
Kano, Satoshi
Murai, Junko
Suzuki, Takayoshi
Tsushima, Nayuta
Mizumachi, Takatsugu
Suzuki, Masanobu
Takashima, Tsuyoshi
Taniyama, Daiki
Sakamoto, Naoya
Fujioka, Yoichiro
Ohba, Yusuke
Homma, Akihiro
author_sort Hamada, Seijiro
collection PubMed
description Recently, Schlafen family member 11 (SLFN11) has been reported to increase the sensitivity of cancer cells to DNA-damaging agents, including platinum derivatives; thus, SLFN11 may be a predictive biomarker for platinum-based chemoradiotherapy (CRT). In this study, we examined whether SLFN11 expression was associated with the therapeutic outcome of platinum-based CRT in head and neck squamous cell carcinoma (HNSCC). We performed immunohistochemical analyses for SLFN11 expression in 161 HNSCC tissues from patients who had been administered cisplatin-based CRT and examined the correlation between SLFN11 expression and progression-free survival (PFS). Additionally, SLFN11 expression was examined in 10 paired samples obtained before and after CRT in patients with local failure. Furthermore, in vitro experiments were performed using several HNSCC cell lines and isogenic SLFN11-knockout cells to assess the association between SLFN11 expression and drug sensitivity. PFS was found to be significantly better in the SLFN11-positive group than in the SLFN11-negative group among the 161 patients (5-year PFS: 78.8% vs. 52.8%, respectively, p < 0.001). Similar results were observed for the PFS at each primary site. The percentage of SLFN11 positivity was lower in tumor samples from patients with local failure after CRT than that in the corresponding primary tumors before CRT in 8 of 10 cases. Results of the in vitro assay demonstrated that SLFN11-knockout cells exhibited reduced sensitivity to DNA-damaging agents but not to the non-DNA-damaging agent docetaxel. Our findings suggest that SLFN11 may serve as a potential biomarker for predicting the response of HNSCC patients to platinum-based CRT.
format Online
Article
Text
id pubmed-9892834
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98928342023-02-03 Schlafen family member 11 indicates favorable prognosis of patients with head and neck cancer following platinum-based chemoradiotherapy Hamada, Seijiro Kano, Satoshi Murai, Junko Suzuki, Takayoshi Tsushima, Nayuta Mizumachi, Takatsugu Suzuki, Masanobu Takashima, Tsuyoshi Taniyama, Daiki Sakamoto, Naoya Fujioka, Yoichiro Ohba, Yusuke Homma, Akihiro Front Oncol Oncology Recently, Schlafen family member 11 (SLFN11) has been reported to increase the sensitivity of cancer cells to DNA-damaging agents, including platinum derivatives; thus, SLFN11 may be a predictive biomarker for platinum-based chemoradiotherapy (CRT). In this study, we examined whether SLFN11 expression was associated with the therapeutic outcome of platinum-based CRT in head and neck squamous cell carcinoma (HNSCC). We performed immunohistochemical analyses for SLFN11 expression in 161 HNSCC tissues from patients who had been administered cisplatin-based CRT and examined the correlation between SLFN11 expression and progression-free survival (PFS). Additionally, SLFN11 expression was examined in 10 paired samples obtained before and after CRT in patients with local failure. Furthermore, in vitro experiments were performed using several HNSCC cell lines and isogenic SLFN11-knockout cells to assess the association between SLFN11 expression and drug sensitivity. PFS was found to be significantly better in the SLFN11-positive group than in the SLFN11-negative group among the 161 patients (5-year PFS: 78.8% vs. 52.8%, respectively, p < 0.001). Similar results were observed for the PFS at each primary site. The percentage of SLFN11 positivity was lower in tumor samples from patients with local failure after CRT than that in the corresponding primary tumors before CRT in 8 of 10 cases. Results of the in vitro assay demonstrated that SLFN11-knockout cells exhibited reduced sensitivity to DNA-damaging agents but not to the non-DNA-damaging agent docetaxel. Our findings suggest that SLFN11 may serve as a potential biomarker for predicting the response of HNSCC patients to platinum-based CRT. Frontiers Media S.A. 2023-01-19 /pmc/articles/PMC9892834/ /pubmed/36741698 http://dx.doi.org/10.3389/fonc.2022.978875 Text en Copyright © 2023 Hamada, Kano, Murai, Suzuki, Tsushima, Mizumachi, Suzuki, Takashima, Taniyama, Sakamoto, Fujioka, Ohba and Homma https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Hamada, Seijiro
Kano, Satoshi
Murai, Junko
Suzuki, Takayoshi
Tsushima, Nayuta
Mizumachi, Takatsugu
Suzuki, Masanobu
Takashima, Tsuyoshi
Taniyama, Daiki
Sakamoto, Naoya
Fujioka, Yoichiro
Ohba, Yusuke
Homma, Akihiro
Schlafen family member 11 indicates favorable prognosis of patients with head and neck cancer following platinum-based chemoradiotherapy
title Schlafen family member 11 indicates favorable prognosis of patients with head and neck cancer following platinum-based chemoradiotherapy
title_full Schlafen family member 11 indicates favorable prognosis of patients with head and neck cancer following platinum-based chemoradiotherapy
title_fullStr Schlafen family member 11 indicates favorable prognosis of patients with head and neck cancer following platinum-based chemoradiotherapy
title_full_unstemmed Schlafen family member 11 indicates favorable prognosis of patients with head and neck cancer following platinum-based chemoradiotherapy
title_short Schlafen family member 11 indicates favorable prognosis of patients with head and neck cancer following platinum-based chemoradiotherapy
title_sort schlafen family member 11 indicates favorable prognosis of patients with head and neck cancer following platinum-based chemoradiotherapy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892834/
https://www.ncbi.nlm.nih.gov/pubmed/36741698
http://dx.doi.org/10.3389/fonc.2022.978875
work_keys_str_mv AT hamadaseijiro schlafenfamilymember11indicatesfavorableprognosisofpatientswithheadandneckcancerfollowingplatinumbasedchemoradiotherapy
AT kanosatoshi schlafenfamilymember11indicatesfavorableprognosisofpatientswithheadandneckcancerfollowingplatinumbasedchemoradiotherapy
AT muraijunko schlafenfamilymember11indicatesfavorableprognosisofpatientswithheadandneckcancerfollowingplatinumbasedchemoradiotherapy
AT suzukitakayoshi schlafenfamilymember11indicatesfavorableprognosisofpatientswithheadandneckcancerfollowingplatinumbasedchemoradiotherapy
AT tsushimanayuta schlafenfamilymember11indicatesfavorableprognosisofpatientswithheadandneckcancerfollowingplatinumbasedchemoradiotherapy
AT mizumachitakatsugu schlafenfamilymember11indicatesfavorableprognosisofpatientswithheadandneckcancerfollowingplatinumbasedchemoradiotherapy
AT suzukimasanobu schlafenfamilymember11indicatesfavorableprognosisofpatientswithheadandneckcancerfollowingplatinumbasedchemoradiotherapy
AT takashimatsuyoshi schlafenfamilymember11indicatesfavorableprognosisofpatientswithheadandneckcancerfollowingplatinumbasedchemoradiotherapy
AT taniyamadaiki schlafenfamilymember11indicatesfavorableprognosisofpatientswithheadandneckcancerfollowingplatinumbasedchemoradiotherapy
AT sakamotonaoya schlafenfamilymember11indicatesfavorableprognosisofpatientswithheadandneckcancerfollowingplatinumbasedchemoradiotherapy
AT fujiokayoichiro schlafenfamilymember11indicatesfavorableprognosisofpatientswithheadandneckcancerfollowingplatinumbasedchemoradiotherapy
AT ohbayusuke schlafenfamilymember11indicatesfavorableprognosisofpatientswithheadandneckcancerfollowingplatinumbasedchemoradiotherapy
AT hommaakihiro schlafenfamilymember11indicatesfavorableprognosisofpatientswithheadandneckcancerfollowingplatinumbasedchemoradiotherapy